AtriCure traded at $58.97 this Friday October 23rd, decreasing $0.33 or 0.56 percent since the previous trading session. Looking back, over the last four weeks, AtriCure lost 2.96 percent. Over the last 12 months, its price rose by 57.09 percent. Looking ahead, we forecast AtriCure to be priced at 57.72 by the end of this quarter and at 54.13 in one year, according to Trading Economics global macro models projections and analysts expectations.
AtriCure, Inc. is a provider of technologies for the treatment of atrial fibrillation (Afib) and related conditions. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue, systems designed for the exclusion of the left atrial appendage, and devices designed to block pain by temporarily ablating peripheral nerves. These devices are developed and marketed to medical centers globally. Its ablation and left atrial appendage management (LAAM) products are used by physicians during both open-heart and minimally invasive procedures. Its products for open and minimally invasive ablation includes Isolator Synergy Clamp and Multifunctional Pens and Linear Ablation Devices. Its Product for open ablation are cryoICE Cryoablation System. Its product for minimally invasive ablation are EPi-Sense Guided Coagulation System with VisiTrax Technology. Its products for appendage management includes AtriClip System and LARIAT System.